Researchers found a direct-to-the-brain treatment for type 2 diabetes (T2D) by injecting a single dose of Fibroblast Growth Factor 1 (FGF1) hormone into the brain via the intra-nasal route. The mice experienced relief (for 17 weeks) from type 2 diabetes (T2D) with no change in diet or weight. A 17-week mice phase is equivalent to a 12-year human phase. Authors say a relief from type 2 diabetes is not dependent on weight loss, diet changes or exercises.
Researchers believe that the brain can control blood glucose levels after injecting FGF1 hormone. This type of diabetes remission was seen only in bariatric surgery. There is a wide range of medications available. But all the treatments require substantial weight loss for the success of the treatment. This experiment unlikely to initiate similar approaches in humans. Authors say intranasal delivery of FGF1 to the brain is possible. The study was led by Michael W. Schwartz (endocrinologist), Jarrad M. Scarlett (gastroenterologist) and Jennifer M. Rojas (molecular physiologist). The study was published in the Nature Medicine.
A study found an increased risk of atherosclerotic cardiovascular disease in postmenopausal women diagnosed with diabetes even if they are taking statins therapy. In general, statins reduce the risk of atherosclerotic cardiovascular disease. Atherosclerotic cardiovascular events are.
But, statin therapy increases the risk of diabetes. Researchers hypothesized that the risk of atherosclerotic cardiovascular disease will be milder. The study shows it is important for postmenopausal women to monitor, diagnose and prevent diabetes, even if they are taking statins. The lead author of the study was Prof Yunsheng Ma and co-author of the study was JoAnn E Manson, UMass Medical School. The study was published in the European Journal of Epidemiology.
Gestational diabetes (GD) leads to type 2 diabetes (T2D) due to genes. Gene expression changes due to a change to histones in our cells. A poor lifestyle choice leads to a change in histones. A two-year study measured the levels of histones of four groups of women during the pregnancy and postpartum. They are.
Researchers found that histones are different between women who have type 2 diabetes (T2D) after gestational diabetes and women without type 2 diabetes (T2D) after gestational diabetes. Prof Leigh says with this study, medical professionals can predict the development of type 2 diabetes (T2D) in patients with gestational diabetes. The author of the study was Prof Leigh Ackland, Deakin University. The study was published in the Journal of Clinical Endocrinology and Metabolism.
A study conducted by Paul Thornalley, a Prof at Warwick suggested red grapes and oranges (taken together) offers a new treatment for obesity, diabetes and cardiovascular disease (CVD). The new treatment was found to be more effective than metformin. Methylglyoxal (MG) is the key driver for the harmful effects of sugar in the body. High levels of MG and high-calorie diet is the cause of the insulin resistance. Methylglyoxal (MG) damages blood vessels and also increases cholesterol levels (a risk factor for CVD).
Researchers found that red grapes contain trans-resveratrol (tRES) and oranges contain hesperetin (HESP). A combination of red grapes and oranges increases Glo1. Glo1 is an enzyme that neutralizes the compound called methylglyoxal (MG). The study received funding from the UK's innovation agency, Innovate UK. The study was published in the journal Diabetes.
The Diabetes News Chronicle does not provide medical advice, diagnosis or treatment. Information in Diabetes News Chronicle is to support and not to replace medical advice given by the surgeon or physician or doctor. Published article is not a medical advice by the OWNER of the "Diabetes News Chronicle" website or by the AUTHOR of the article.
Published by Jammi Vasista, Chennai, India.